What is the company's outlook for full-year 2002?

Pfizer anticipates double-digit full-year 2002 revenue growth at current exchange rates, margin improvements, and continued investments in product support and R&D, which is expected to be around $5.2 billion for the year. They also expect merger-related cost savings from the Warner-Lambert merger to reach $1.8 billion for 2002.

What are the key strategic developments mentioned in the report?

The most significant strategic development is the announced definitive agreement to merge with Pharmacia Corporation in a stock-for-stock transaction valued at approximately $60 billion. This transaction is expected to close by year-end 2002 or early 2003. Additionally, Pfizer is exploring strategic options, including potential sales, for its Adams confectionery business and Schick-Wilkinson Sword shaving products business, and has entered into an agreement to sell its Tetra business.

How is the company managing its financial resources and returning value to shareholders?

Pfizer generated strong operating cash flow, with $6.449 billion provided by operating activities in the first nine months of 2002. The company continues to actively repurchase its common stock, with $4.726 billion spent on share repurchases in the first nine months of 2002, and has increased its share-purchase program authorization to $16 billion. A quarterly cash dividend of $0.13 per share was declared, indicating a commitment to returning capital to shareholders.

What are the primary risks and uncertainties facing Pfizer?

Key risks and uncertainties include the success of research and development activities and regulatory approvals, competitive developments for existing and new products, manufacturing challenges, patent expirations leading to generic competition, healthcare cost containment trends, potential U.S. legislation affecting pharmaceutical pricing, environmental liabilities, legal defense costs, patent and intellectual property protection, interest rate and foreign currency fluctuations, governmental regulations, and the integration of the proposed Pharmacia acquisition, as well as the potential sales of certain businesses.

PFE 10-Q Quarterly Report Q3 FY2002 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported strong financial performance for the nine months ended September 29, 2002, with revenues increasing by 9% to $25.177 billion and net income growing by 8% to $6.270 billion, or $1.02 per diluted share. The company's pharmaceutical segment continues to be the primary growth driver, with key products like Lipitor, Norvasc, and Zoloft showing significant year-over-year revenue increases. The company also announced a major strategic development: a definitive agreement to merge with Pharmacia Corporation, a stock-for-stock transaction valued at approximately $60 billion, expected to close by year-end 2002 or early 2003. Operationally, Pfizer demonstrated effective cost management, with cost of sales growing slower than revenue and significant merger-related synergies from the Warner-Lambert acquisition. The company also continued its robust share repurchase program and declared a quarterly dividend, signaling confidence in its financial health and commitment to returning value to shareholders. Despite ongoing litigation risks, particularly related to patent challenges for key drugs, Pfizer's financial results and strategic outlook appear positive.

Key Highlights

1Revenues increased 9% year-over-year to $25.177 billion for the nine months ended September 29, 2002.
2Net income rose 8% to $6.270 billion, or $1.02 per diluted share, for the same period.
3Announced a definitive agreement to merge with Pharmacia Corporation in a stock-for-stock transaction valued at approximately $60 billion.
4Pharmaceutical segment revenue grew 10% for the nine months ended September 29, 2002, driven by strong performance of key products like Lipitor and Norvasc.
5The company repurchased approximately $4.7 billion of common stock in the first nine months of 2002.
6Merger-related cost savings from the Warner-Lambert acquisition reached approximately $1.3 billion for the first nine months of 2002.
7The company anticipates double-digit full-year 2002 revenue growth and R&D investment of about $5.2 billion.

PFIZER INC Quarterly Report for Q3 Ended Sep 29, 2002

Summary

Key Highlights

Frequently Asked Questions